James Basta is EVP, General Counsel of Intellia Therapeutics, Inc.. Currently has a direct ownership of 81,571 shares of NTLA, which is worth approximately $1.21 Million. The most recent transaction as insider was on Mar 04, 2024, when has been sold 2,297 shares (Common Stock) at a price of $32.99 per share, resulting in proceeds of $75,778. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 81.6K
0% 3M change
47.56% 12M change
Total Value Held $1.21 Million

JAMES BASTA Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 04 2024
SELL
Open market or private sale
$75,778 $32.99 p/Share
2,297 Reduced 2.74%
81,571 Common Stock
Mar 01 2024
BUY
Grant, award, or other acquisition
-
32,394 Added 27.86%
83,868 Common Stock
Jan 03 2024
SELL
Open market or private sale
$112,095 $29.46 p/Share
3,805 Reduced 6.88%
51,474 Common Stock
Mar 02 2023
SELL
Open market or private sale
$47,741 $43.88 p/Share
1,088 Reduced 1.93%
55,279 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
36,808 Added 39.5%
56,367 Common Stock
Jan 04 2023
SELL
Open market or private sale
$42,344 $37.21 p/Share
1,138 Reduced 5.5%
19,559 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
20,697 Added 50.0%
20,697 Common Stock

Also insider at

KURA
Kura Oncology, Inc. Healthcare
JB

James Basta

EVP, General Counsel
Cambridge, MA

Track Institutional and Insider Activities on NTLA

Follow Intellia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA